NasdaqGM:LGNDPharmaceuticals
Assessing Ligand Pharmaceuticals (LGND) Valuation After Recent Share Price Weakness And Strong 1 Year Return
Event context and recent stock performance
Ligand Pharmaceuticals (LGND) has come into focus after a period in which its shares have moved lower over the past month and past 3 months, while still showing a positive 1 year total return.
At a last close of US$183.83, the company carries a value score of 3, with annual revenue of US$251.233 million and net income of US$48.581 million, supported by positive annual revenue and net income growth.
See our latest analysis for Ligand...